Secondary Failure of Oral Therapy in Patients With Type 2 Diabetes - How To Overcome It?
Abstract
Background/Aim: Secondary failure of oral therapy occurs after a long period of successful use of oral antidiabetic drugs. The exact mechanism of its occurrence is not known. Recent data suggest heterogeneity of this phenomenon, analogous that of type 2 diabetes pathogenesis. Research objective was to assess glucoregulation and insulin secretory function before, three months after the use of insulin therapy and three months after the exclusion and re-introduction of oral antidiabetic therapy.
Methods: Forty-nine patients with unsatisfactory glycaemic control were selected and insulin therapy in four daily doses (basal-bolus regimen) was subsequently initiated. Glycaemic regulation and beta cell function (C-peptide and insulinemia) were monitored at three time points: before starting insulin therapy, three months after initiating insulin and three months after discontinuing insulin and resuming the previously used oral antidiabetics.
Results: After the introduction of insulin therapy, there was a significant improvement in glycaemic regulation parameters (p < 0.001). Improvements in beta-cell function and reductions in insulin resistance were confirmed during the period after insulin therapy (p < 0.001). However, a certain deterioration in these parameters was observed following the discontinuation of insulin therapy. Additionally, there was a slight decrease in C-peptide and an increase in insulinemia, though these changes were not statistically significant.
Conclusion: Application of intensified insulin therapy for three months leads to improvement of glucoregulation and partial recovery of the secretory function of the endocrine pancreas. The reintroduction of oral antidiabetic therapy led to a slight worsening of the observed parameters, although this change was not statistically significant.
References
Wysham C, Shubrook J. Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications. Postgrad Med. 2020 Nov;132(8):676-86. doi: 10.1080/00325 481.2020.1771047.
Chen YN, Chen SY, Zeng LJ, Ran JM, Wu MY. Progressive decrease of proinsulin secretion in sulphonylurea-treated type 2 diabetes.; J Biomed Sci. 2005;62(1):5-8. doi: 10.1080/09674845.2005.11732679.
Chen YN, Chen SY, Zeng LJ, Ran JM, Xie B, Wu MY, et al. Secondary sulphonylurea failure: what pathogenesis is responsible? Br J Biomed Sci. 2003;60(1):9-13. doi: 10.1080/09674845.2003.11783670.
Brown JB, Conner C, Nicholas GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010;33(3):501. doi: 10.2337/dc09-1749.
Cernea S, Dobreanu M. Diabetes and beta cell function: from mechanisms to evaluation and clinical implications. Biochem Med (Zagreb). 2013;23(3):266-80. doi: 10.11613/bm.2013.033.
Cha J, Aguayo-Mazzucato C, Thompson PJ. Pancreatic beta-cell senescence in diabetes: mechanisms, markers and therapies. Front Endocrinol (Lausanne). 2023 Aug 31;14:1212716. doi: 10.3389/fendo.2023.1212716.
Utzschneider KM, Younes N, Butera NM, Balasubramanyam A, Bergenstal RM, Barzilay J, et al; GRADE Research Group. Impact of insulin sensitivity and β-cell function over time on glycemic outcomes in the glycemia reduction approaches in diabetes: A Comparative Effectiveness Study (GRADE): differential treatment effects of dual therapy. Diabetes Care. 2024 Apr 1;47(4):571-9. doi: 10.2337/dc23-1059.
Cersosimo E, Solis-Herrera C, Trautmann ME, Malloy J, Triplitt CL. Current assessment of pancreatic β-cell function: review of methods and clinical applications. Diabetes Rev. 2014 Jan;10(1):2-42. doi: 10.2174/1573399810666140214093600.
Lee J, Liu R, de Jesus D, Kim BS, Ma K, Moulik M, et al. Circadian control of beta-cell function and stress responses. Diabetes Obes Metab. 2015 Sep;17 Suppl 1(0 1):123-33. doi: 10.1111/dom.12524.
Reaven GM. HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not? Diab Vasc Dis Res. 2009 Apr;6(2):133-8. doi: 10.1177/1479164109336038.
Eurich DT, Simpson SH, Majumdar SR. Secondary failure rates assotiated with metformin and sulphonilurea therapy for type 2 diabetes mellitus. Pharmacotherapy. 2005;25(6):810-6. doi:10.1592/phco.2005.25.6.810.
Kimani CN, Reuter H, Kotzé SH, Muller CJF. Current issues regeneration of pancreatic beta cells by modulation of molecular targets using plant-derived compounds: pharmacological mechanisms and clinical potential. Mol Biol. 2023 Jul 26;45(8):6216-45. doi: 10.3390/cimb45080392.
Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, et al. Effect of intensive insulin therapy on beta-cell function and glycemic control in patients with newly diagnosed type 2 diabetes: a multicentric randomised parallel group trial. Lancet. 2008;371(9626):1753-60. doi: 10.1016/S0140-6736(08)60762-X.
Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013 Sep;1(1):28-34. doi: 10.1016/S2213-8587(13)70006-8.
Karacaer C, Demirci T, Cengiz H, Varim C, Tamer A. The effect of short-term intensive insulin therapy in newly-diagnosed Type-2 diabetic patients. Pak J Med Sci. 2021 Nov-Dec;37(7):1972-8. doi: 10.12669/pjms.37.7.4013.
Weng J. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9. J Diabetes. 2017 Oct;9(10):890-3. doi: 10.1111/1753-0407.12581.
Aschner P. Insulin therapy in type 2 diabetes. Am J Ther. 2020 Jan/Feb;27(1):e79-e90. doi: 10.1097/MJT.0000000000001088.
Galdón Sanz-Pastor A, Justel Enríquez A, Sánchez Bao A, Ampudia-Blasco FJ. Current barriers to initiating insulin therapy in individuals with type 2 diabetes. Front Endocrinol (Lausanne). 2024 Mar 14;15:1366368. doi: 10.3389/fendo.2024.1366368.
Retnakaran R, Emery A, Ye C, Harris SB, Reichert SM, McInnes N, et al. Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes (RESET-IT Main): A 2-year randomized controlled trial. Diabetes Obes Metab. 2021 Aug;23(8):1926-35. doi: 10.1111/dom.14421.
Choi H, Kramer CK, Zinman B, Connelly PW, Retnakaran R. Effect of short-term intensive insulin therapy on the incretin response in early type 2 diabetes. Diabetes Metab. 2019 Apr;45(2):197-200. doi: 10.1016/j.diabet.2018.01.003.
Saisho Y. Postprandial C-peptide to glucose ratio as a marker of β cell function: implication for the management of type 2 diabetes. Int J Mol Sci. 2016 May 17;17(5):744. doi: 10.3390/ijms17050744.
Retnakaran R, Pu J, Emery A, Harris SB, Reichert SM, Gerstein HC, et al. Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes. Nat Commun. 2023 Jul 27;14(1):4514. doi: 10.1038/s41467-023-40287-w.
Andrews WJ, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R, et al. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes. 1984 Jul;33(7):634-42. doi: 10.2337/diab.33.7.634.
Campos C. Chronic hyperglycemia and glucose toxicity: pathology and clinical sequelae. Postgrad Med. 2012 Nov;124(6):90-7. doi: 10.3810/pgm.2012.11.2615.
Gamble J, Simpson SH, Brown LC, Johnson JA. Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis. Open Med. 2008;2(2):e26-38. PMID: 21602937;
Halban PA, Polonsky KS, Bowden DW, Hawkins MA, Ling C, Mather KJ, et al. β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care. 2014 Jun;37(6):1751-8. doi: 10.2337/dc14-0396.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).